WinstonWınston
ZIVO Bioscience logo

ZIVO Bioscience

ZIVO
Biotechnology · Healthcare
Price
$4.14
-0.66 (-13.75%)
Market Cap
$16.1M
Winston Score
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+200.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 1.3M (2021) → 3.8M (2025)

ZIVO Bioscience is a small biotech company that develops natural compounds from algae. Its main focus is on a microalgae strain called Chlorella, which it believes contains bioactive ingredients that could support immune health. The company is working on products for two main markets: animal health (like poultry and livestock feed additives) and human health supplements.

ZIVO earns revenue through licensing agreements, where it partners with larger companies that pay to use its algae-derived ingredients in their own products. It is a very small, early-stage company based in the United States with a market cap near zero, meaning it has not yet built a large commercial business. The massive negative operating margin reflects heavy spending on research with little revenue coming in, and the key risk is that the company may need to raise more cash to survive while it waits for its products to gain regulatory approval and commercial traction.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-100.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-63.8% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$4M/ year

Rising (+38% vs prior year)

>1,000% of revenue

202.3x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

62.1%ownership

Declining

Insider ownership declining — could be dilution or selling

Cash Runway

~0 months

$67,058 cash & investments

Quarterly Free Cash Flow

Short runway — potential dilution ahead through share issuance

Heavy R&D investment

ZIVO Bioscience is putting 3641% of revenue into R&D and that number is rising. That's 202.3x the sector average.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
N/A
Data not available
Operating Margin
N/A
Data not available
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-24.3%
Shrinking sales (-24.3% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
-2761.5%
Burning cash (-2761.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial